Mechanisms of drug resistance in status epilepticus

Epilepsia

Volumn 48, Issue SUPPL. 8, 2007, Pages 74-77

  Löscher, Wolfgang ^a,b  

^a CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Antiepileptic drugs; Epilepsy; GABA receptors; P glycoprotein; Receptor trafficking

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CYCLOSPORIN A; DIAZEPAM; DIZOCILPINE; FOSPHENYTOIN SODIUM; GLYCOPROTEIN P; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENOBARBITAL; PHENYTOIN; TARIQUIDAR; VALPROIC ACID;

BLOOD BRAIN BARRIER; BRAIN DAMAGE; CLINICAL STUDY; CONFERENCE PAPER; DISEASE CONTROL; DISEASE DURATION; DISEASE MODEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG TOLERANCE; DRUG TRANSPORT; DRUG TREATMENT FAILURE; EFFUSION; EPILEPTIC STATE; EPILEPTOGENESIS; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTICONVULSANTS; BENZODIAZEPINES; BRAIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; HUMANS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; RATS; RECEPTORS, GABA; STATUS EPILEPTICUS;

EID: 35748954338     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01357.x     Document Type: Conference Paper

References (25)

1. Avanzini G 2006) Is tolerance to antiepileptic drugs clinically relevant? Epilepsia 47 : 1285 1287.
2. Bankstahl JP, Potschka H, Löscher W 2006) Pharmacological characterisation of a status epilepticus model induced by prolonged electrical stimulation of the amygdala in rats. FENS Abstr 3 : A024.4.
3. Bankstahl JP, Potschka H, Löscher W 2007) Lack of relationship between response to antiepileptic treatment and P-glycoprotein expression in the pilocarpine model of status epilepticus. Naunyn Schmiedebergs Arch Pharmacol 375 (Suppl. 1 55.
4. Brandt C, Potschka H, Löscher W, Ebert U 2003) N-methyl-D-aspartate receptor blockade after status epilepticus protects against limbic brain damage but not against epilepsy in the kainate model of temporal lobe epilepsy. Neuroscience 118 : 727 740.
5. Brandt C, Gastens AM, Sun MZ, Hausknecht M, Löscher W 2006) Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 51 : 789 804.
6. Chen JW, Wasterlain CG 2006) Status epilepticus: pathophysiology and management in adults. Lancet Neurol 5 : 246 256.
7. DeLorenzo RJ 2006) Epidemiology and clinical presentation of status epilepticus. Adv Neurol 97 : 199 215.
8. Fujikawa DG 2005) Prolonged seizures and cellular injury: understanding the connection. Epilepsy Behav 7 (Suppl. 3 S3 S11.
9. Goodman JH 1998) Experimental models of status epilepticus. In Peterson SL, Albertson TE (Eds) Neuropharmacology methods in epilepsy research. CRC Press, Boca Raton, pp. 95 125.
10. Iannetti P, Spalice A, Parisi P 2005) Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 46 : 967 969.
11. Jones DM, Esmaeil N, Maren S, Macdonald RL 2002) Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res 50 : 301 312.
12. + sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 17 : 7532 7540.
13. Lowenstein DH 2006) The management of refractory status epilepticus: an update. Epilepsia 47 (Suppl. 1 35 40.
14. Löscher W 2002) Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and models with spontaneous recurrent seizures. Epilepsy Res 50 : 105 123.
15. Löscher W, Potschka H 2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6 : 591 602.
16. Löscher W, Schmidt D 2006) Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47 : 1253 1284.
17. Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG 1998) Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Research 814 : 179 185.
18. Mazarati AM, Wasterlain C, Shinmei S 2003) Enhancement of antiepileptic drug treatment of experimental status epilepticus through inhibition of P-glycoprotein. Epilepsia 44 (Suppl. 9 109.
19. Naylor DE, Liu H, Wasterlain CG 2005) Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25 : 7724 7733.
20. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, Aliprandi M, Bagnati R, Fanelli R, D'Incalci M, Samanin R, Vezzani A 2002) Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 22 : 5833 5839.
21. Rogawski MA, Löscher W 2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5 : 553 564.
22. Schmitt F, Merschhemke M, Dehnicke C, Meencke H 2007) Status epilepticus with tonic seizures in non-lesional epilepsy: multidrug transporter inhibitor (verapamil) attenuates malignant treatment course. Epilepsia (in press).
23. Sisodiya SM, Thom M 2003) Widespread upregulation of drug-resistance proteins in fatal human status epilepticus. Epilepsia 44 : 261 264.
24. Young GB 2006a) Status epilepticus and refractory status epilepticus: introductory and summary statements. Adv Neurol 97 : 183 185.
25. Young GB 2006b) Status epilepticus and brain damage: pathology and pathophysiology. Adv Neurol 97 : 217 220.